COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countriesEng Hooi Tan, Daniel Prieto‐Alhambra, Jitendra Jonnagaddala et al.|Lara D. Veeken|2021Cited by 53
Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort studyErica A. Voss, Rohit Vashisht, Kevin Haynes et al.|EClinicalMedicine|2023Cited by 27
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDISKristin Kostka, Nicole G. Weiskopf, Hong Zhu et al.|Clinical Epidemiology|2022Cited by 26
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and BevacizumabCindy X. Cai, Patrick Ryan, Scott L. Zeger et al.|Ophthalmology Retina|2024Cited by 16
Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort StudyAzza Shoaibi, Patrick Ryan, Evan Minty et al.|Drug Safety|2022Cited by 10